下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源，从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
99.3分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤来源的细胞外微囊泡治疗急性肾衰竭：一项实验研究
英文原题：Tumour-Derived, Extracellular Microvesicles in the Treatment of Acute Renal Failure: An Experimental Study.
研究概要
背景/目的：本研究比较了来源于小鼠 L929 肉瘤细胞和小鼠间充质干细胞（MSCs）的细胞外微囊泡（MVs）的治疗效果。
中文摘要
背景/目的：比较来源于小鼠L929肉瘤细胞和小鼠间充质干细胞（MSC）的细胞外微囊泡（MV）的治疗效果。方法：使用急性肾损伤（AKI）小鼠模型。结果：与小鼠外周血单个核细胞（PBMC）来源MV不同，L929细胞来源MV（L929-MV）和MSC来源MV（MSC-MV）均提高AKI小鼠生存率并显著改善肾功能，表现为尿白蛋白和血清肌酐水平下降。此外，L929-MV和MSC-MV治疗增加AKI小鼠脾脏CD4+CD25+FOXP3+调节性T细胞比例，同时减少促炎性CD4+CD44+ T细胞。结论：研究结果凸显肿瘤来源MV促进器官修复及发挥细胞保护性免疫调节作用的潜力。
展开英文摘要原文
Background/Objectives : This investigation compared the therapeutic efficacy of extracellular microvesicles (MVs) derived from murine L929 sarcoma cells and murine mesenchymal stem cells (MSCs). Methods : A mouse model of acute kidney injury (AKI) was used. Results : Both MVs from L929 cells (L929-MVs) and MSCs (MSC-MVs), unlike those obtained from murine peripheral blood mononuclear cells (PBMCs), enhanced survival rates in AKI mice and significantly improved kidney function. This was indicated by decreased levels of urine albumin and serum creatinine. Furthermore, treatment with L929-MVs and MSC-MVs elevated the proportions of CD4+CD25+FOXP3+ regulatory T cells while reducing the presence of pro-inflammatory CD4+CD44+ T cells in the spleens of AKI mice. Conclusions : the results highlight the potential of tumour-derived MVs to facilitate organ repair and exert cytoprotective immunomodulatory effects.
论文信息
- 作者
- Seledtsova GV、Seledtsov VI、Dorzhieva AB、Ivanova IP、Khabalova TS、Darinskas A、von Delwig AA
- 单位
- Institute for Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia.Russia
- 期刊
- Medical sciences (Basel, Switzerland)2025 Apr 1
- 原文标识
- PubMed 40265382 · DOI 10.3390/medsci13020035